Literature DB >> 7642691

The use of the Calvert formula to determine the optimal carboplatin dosage.

L J van Warmerdam1, S Rodenhuis, W W ten Bokkel Huinink, R A Maes, J H Beijnen.   

Abstract

Carboplatin is a chemotherapeutic agent frequently used in the treatment of various malignancies. The myelotoxicity and clinical efficacy of carboplatin correlate with the clearance of the drug, which is correlated to the glomerular filtration rate (GFR). Dosing of this agent based solely upon the patients body surface area is therefore not accurate enough; the GFR, and thus the clearance of carboplatin differ in each patient irrespective of the body area. Consequently, some patients undergo a higher systemic exposure, expressed as the area under the plasma concentration/time curve (AUC), than others when dosages of carboplatin are given on the basis of the body surface area. A high AUC correlates with increased toxicity, thus increasing the risks of the treatment, but in the case of a low AUC the therapeutical efficacy decreases. This indicates that an individual dosing strategy is warranted to obtain the optimal AUC. In this article, the development and application of a simple equation, known as the Calvert formula, are discussed. This formula can be used to calculate the carboplatin dose accurately in order to obtain a target AUC by using only the GFR. The formula is: dose (mg) = AUC (mg ml-1 min) x [GFR (ml/min) + 25 (ml/min)]. This formula has proven to be, in both retrospective and prospective studies, a reliable tool to calculate the optimal dose of carboplatin Future studies should determine the value of the creatinine clearance as a measure for the GFR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642691     DOI: 10.1007/bf01218365

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.

Authors:  D R Newell; R A Eeles; L A Gumbrell; F E Boxall; A Horwich; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA.

Authors:  C Chantler; E S Garnett; V Parsons; N Veall
Journal:  Clin Sci       Date:  1969-08       Impact factor: 6.124

3.  Calculation of 51Cr-EDTA clearance in children from the activity in one plasma sample by transformation of the biexponential plasma time-activity curve into a monoexponential with identical integral area below the time-activity curve.

Authors:  S Groth
Journal:  Clin Physiol       Date:  1984-02

4.  Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.

Authors:  R L Krigel; C S Palackdharry; K Padavic; N Haas; D Kilpatrick; C Langer; R Comis
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

5.  The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis.

Authors:  W J Childs; E J Nicholls; A Horwich
Journal:  Ann Oncol       Date:  1992-04       Impact factor: 32.976

Review 6.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

Authors:  N M Marina; J Rodman; S J Shema; L C Bowman; E Douglass; W Furman; V M Santana; M Hudson; J Wilimas; W Meyer
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

Review 9.  Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

Authors:  H Calvert; I Judson; W J van der Vijgh
Journal:  Cancer Surv       Date:  1993

10.  Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

Authors:  L M Reyno; M J Egorin; R M Canetta; D I Jodrell; K D Swenerton; J L Pater; J N Burroughs; M J Novak; R Sridhara
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more
  12 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.

Authors:  Kenneth F Grossmann; Howard Colman; Wallace A Akerley; Michael Glantz; Yuko Matsuoko; Andrew P Beelen; Margaret Yu; John F De Groot; Robert D Aiken; Jeffrey J Olson; Jeffery J Olsen; Brent A Evans; Randy L Jensen
Journal:  J Neurooncol       Date:  2012-08-30       Impact factor: 4.130

4.  Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.

Authors:  Kathryn M Field; Suzanne Kosmider; Michael Jefford; Michael Michael; Ross Jennens; Michael Green; Peter Gibbs
Journal:  J Oncol Pract       Date:  2008-05       Impact factor: 3.840

5.  Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.

Authors:  Mustafa E Ibrahim; Cara Chang; Yichun Hu; Susan L Hogan; Nickie Mercke; Madeleine Gomez; Cindy L O'Bryant; Daniel W Bowles; Blessy George; Xia Wen; Brian Buckley; Lauren Aleksunes; Melanie S Joy
Journal:  Eur J Clin Pharmacol       Date:  2018-09-15       Impact factor: 2.953

6.  Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study.

Authors:  Christoph Aderhold; Guido Manuel Grobschmidt; Alexander Sauter; Anne Faber; Karl Hörmann; Johannes David Schultz
Journal:  Oncol Lett       Date:  2014-07-04       Impact factor: 2.967

7.  Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Authors:  Muneaki Shimada; Hiroaki Itamochi; Junzo Kigawa
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

Review 8.  Translating pharmacogenomics: challenges on the road to the clinic.

Authors:  Jesse J Swen; Tom W Huizinga; Hans Gelderblom; Elisabeth G E de Vries; Willem J J Assendelft; Julia Kirchheiner; Henk-Jan Guchelaar
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

9.  Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya.

Authors:  Amsalu Degu; Peter Njogu; Irene Weru; Peter Karimi
Journal:  Gynecol Oncol Res Pract       Date:  2017-10-18

Review 10.  Prevention of Chemotherapy-Induced Nephrotoxicity in Children with Cancer.

Authors:  Fatemeh Ghane Sharbaf; Hamid Farhangi; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2017-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.